# EDGAR Filing Document

**Accession Number:** 0001997296
**File Stem:** 0000000000-25-006486
**Filing Date:** 2025-6
**Character Count:** 3982
**Document Hash:** c065ad16e21994fd46ea28b97f77fdb4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-006486.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0000000000-25-006486

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250620

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Medicus Pharma Ltd.
- **CENTRAL INDEX KEY:** 0001997296
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981778211
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-42408

**BUSINESS ADDRESS:**
- **STREET 1:** 300 CONSHOHOCKEN STATE RD.
- **STREET 2:** SUITE 200
- **CITY:** W. CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 610-540-7515

**MAIL ADDRESS:**
- **STREET 1:** 300 CONSHOHOCKEN STATE RD.
- **STREET 2:** SUITE 200
- **CITY:** W. CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001062993-25-011673

## Text-Extract

```

                                                             June 20, 2025

Raza Bokhari
Executive Chairman and Chief Executive Officer
Medicus Pharma Ltd.
300 Conshohocken State Rd. Suite 200
W. Conshohocken, PA 19428

       Re: Medicus Pharma Ltd.
           Preliminary Proxy Statement on Schedule 14A
           Filed June 13, 2025
           File No. 001-42408
Dear Raza Bokhari:

       We have reviewed your filing and have the following comments.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Preliminary Proxy Statement on Schedule 14A
Proposal 5 - Share Consolidation or Share Split, page 31

1.     We note that Proposal 5 is seeking shareholder approval of a special
resolution that
       would authorize the Board of Directors to approve a consolidation or
share split of the
       Company's Common Shares "at a consolidation or share split ratio...to be
determined
       by the Board in its sole discretion". Please revise here and throughout
your
       preliminary proxy statement to disclose a possible range of the
potential consolidation
       ratio, or advise.
2.     Please revise your disclosure to provide further details about the
reasons for the
       potential consolidation or share split including, but not limited to,
the intended goals
       of a consolidation or share split and why such actions would be
necessary or desirable
       in furtherance of the Company's business objectives or capital raising
activities.
Certain Risks Associated with the Share Reorganization, page 31

3.     Please revise your disclosure to include relevant risks associated with
a potential share
       consolidation. Such risks may include that a consolidation may decrease
the liquidity
 June 20, 2025
Page 2

       of your common stock, may not increase the price of your common stock in
the long
       term, and that it may cause you to fall out of compliance with the
Nasdaq Continued
       Listing Standards, if true.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Please contact Joshua Gorsky at 202-551-7836 or Laura Crotty at
202-551-7614 with
any other questions.

                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences
cc:   Christopher J. Cummings

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._